Bill Liao
Venture Partner @ SOSV
Cork, Ireland
Bill Liao is a seed investor at SOSV in Cork focused on Biotechnology and Health Care. Bill Liao joined Founders Pledge as Pledger in 2020. Bill Liao is the European Investment Partner at SOSV, investing in, supporting and mentoring companies and startups at all stages of growth. Bill Founded SOSV’s biotech practice and runs IndieBio in Europe. Bill comes to SOSV with a wealth of experiences, both in the public and private sectors. Aco-founder of CoderDojo, a free global network formed to assist young people with learning computer programming, Bill also co-founded XING, a pioneering enterprise social networking platform. Prior to these endeavors, Bill served as COO of Davnet, a telecommunications carrier. Bill has also distinguished himself as a diplomat, serving as a special diplomatic envoy for St Kitt’s and Nevis, with an emphasis on sustainable development and the environment. Author of three books, he is a regular speaker at many events and venues such as The London School of Economics, The World Economic Forum, The Globe Forum in Sweden, The House of Commons and TED as well as TEDx. He is Founder of WeForest that has planted over 9 million trees globally.
- Total investments:
- 258
- Last investment:
- Lead investor:
- 36%
Last updated:
For AI agents: llms.txt
Industries Bill Liao invests in
Stages Bill Liao invests in
Countries Bill Liao invests in
Round sizes
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Round size
- Seed
- $100k–$2.5M
- Pre-Seed
- $66k–$500k
- Convertible Note
- $130k–$3.6M
Investment Focus
Industry
- Biotechnology 65 (25%)
- Health Care 33 (13%)
- Medical 15 (6%)
- Medical Device 12 (5%)
- Life Science 10 (4%)
Stage
- Seed 79 (31%)
- Convertible Note 42 (16%)
- Pre-Seed 18 (7%)
- Series A 10 (4%)
- Venture - Series Unknown 8 (3%)
Country
- Ireland 31 (12%)
- United States 20 (8%)
- United Kingdom 16 (6%)
- Canada 9 (3%)
- Austria 5 (2%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. | $3.5M / Venture - Series Unknown / Mar 12, 2026 | ||
| Microendo’s mission is to protect and care for the environment. Environmental damage due to climate change poses great risk to crop security. By harnessing the natural microbiota of the plants we develop products that are in harmony with the environment. We take the microorganisms from your own plants, identify their needs and provide you with atailored biofertilizer. This biofertilizer is personalized to each crop, fully organic and naturally helps to increase crop health & crop yield. | Seed / Jan 01, 2025 | ||
| CroíValve is a developed a safe, effective, easy to use, percutaneous solution for treating all patients with severe Tricuspid Regurgitation | $16M / Series B / Aug 07, 2024 | ||
| Flow Neuroscience is a healthcare company that develops depression treatment devices that combines an easy-to-use brain stimulation headset with a personalized mobile app to target both the physical and behavioral elements of Major Depressive Disorder (MDD). The company's wearable stimulates a patient's left frontal lobe, the area of thebrain that has often lowered activity in people suffering from depression.Flow Neuroscience combines their wearable with a mobile app that nudges users to behaviors that will help lessen the effects of their depression, including exercise and regular sleeping patterns.The company's hope is to make available for the public a treatment that's currently only used in clinics specialized in brain stimulation. It also wants to make the treatment affordable enough to seriously challenge a dominant pharmaceuticals industry. | Convertible Note / Jul 18, 2024 | ||
| GlowDx is decentralising molecular testing through point-of-care testing using a novel molecular technology. This enables local access, reducing both the economic and disease burden of patients. | Convertible Note / Jun 18, 2024 | ||
| Sundew is a biotechnology company that provides biological services for the treatment of aquatic pests and diseases. The company was founded in 2018 and is headquartered in Copenhagen, | Series B / Jun 17, 2024 | ||
| VisusNano Ltd. is a privately held pre-clinical company developing a drug-eluting intraocular lens implant, for use in patients undergoing cataract surgery. By improving patient outcomes, obviating the need for eye drops after surgery, and avoiding the need for laser treatment after surgery, our project has the potential to revolutionise cataractsurgery in both the human and veterinary markets. | Seed / May 31, 2024 | ||
| DropGenie is building connected hardware to automate gene editing. They are accelerating the pace of discovery through the generation of standardized and compatible scientific information. | Convertible Note / Mar 11, 2024 | ||
| VALANX Biotech is a site-specific protein conjugation platform to enable fast and cost efficient protein-drug-conjugates development. | $2.5M / Seed / Nov 07, 2023 | ||
| Hurdle specializes in tech-bio, bio-infrastructure, personalized wellness, diagnostics, COVID-19 testing platforms, bioinformatics, and AI. | Convertible Note / Sep 13, 2023 | ||
| See all 258 investments → | |||
Co-Investors
About SOSV
SOSV is a global venture capital firm that focuses on deep tech investments through the HAX and IndieBio startup development programs aimed at human and planetary health. The firm invests in startups at their inception, providing support to accelerate their next institutional funding round. HAX offers facilities and engineering resources, whileIndieBio provides services and lab equipment for founders. The firm targets deep technology innovations in the health and environmental sectors.
SOSV Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Arvind Gupta
General Partner
|
|||
Blaine Doyle
Mentor
|
|||
Cyril Ebersweiler
General Partner
|
|||
Deborah Zajac
General Partner
|
|||
Duncan Turner
General Partner
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does Bill Liao invest in?
Bill Liao invests primarily in Biotechnology, Health Care and Medical startups, most often at Seed and Convertible Note stage. Most of the 258 investments tracked by Shizune back companies in Ireland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is Bill Liao's check size?
Bill Liao typically joins rounds of $100k–$2.5M at Seed, $66k–$500k at Pre-Seed and $130k–$3.6M at Convertible Note. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Bill Liao participates in.
How do I contact Bill Liao?
Public channels for Bill Liao include LinkedIn and X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Bill Liao last invest?
The most recent investment recorded for Bill Liao closed in Mar 2026. Shizune tracks 258 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
